Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological Variation of Insulin Resistance, Testosterone and Cardiovascular Risk Factors in Women with Polycystic Ovarian Syndrome: Rimonabant vs Metformin
2006-004447-35Phase 2Completed
- Sponsor
- Hull University Teaching Hospitals
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rimonabant in polycystic ovary syndrome (PCOS), insulin resistance (IR), cardiometabolic risk (CMR) and 1 more (2 arms), sponsored by Hull University Teaching Hospitals. Primary endpoints: Insulin resistance improvement, Hyperandrogenism reduction and 1 more. Started Sep 2006; status: completed.
02
Drugs
rimonabant
03
Conditions
polycystic ovary syndrome (PCOS)insulin resistance (IR)cardiometabolic risk (CMR)Androgenization
Beyond the preview
Go deeper on 2006-004447-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004447-35.